More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults ...

J&J's head of immunodermatology Liza O'Dowd said that the "robust results" with its oral IL-23 drug have the potential to ...

Horsham: Johnson & Johnson has announced that the Company ahs received approval from the U.S. Food and Drug Administration ...